Mar 18, 2026 07:55AM H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Mar 16, 2026 09:02AM Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR): 'evolving into a platform-agnostic, CNS disease focused biotech'

Mar 9, 2026 04:18PM Voyager Therapeutics (VYGR) Tops Q4 EPS by 5c

Feb 12, 2026 08:06AM Voyager Therapeutics chief medical officer to resign Feb. 20

Feb 5, 2026 06:53AM H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Nov 13, 2025 06:43AM Voyager Therapeutics (VYGR) PT Lowered to $25 at H.C. Wainwright

Nov 10, 2025 05:00PM Voyager Therapeutics (VYGR) Tops Q3 EPS by 5c

Nov 10, 2025 04:05PM Voyager Therapeutics (VYGR) files mixed shelf

Nov 10, 2025 01:17PM Voyager Therapeutics (VYGR) PT Raised to $12 at Leerink Partners

Nov 10, 2025 08:02AM Transition Bio and Voyager partner on TDP-43 drugs for ALS and dementia

Aug 6, 2025 06:27PM Voyager Therapeutics (VYGR) Misses Q2 EPS by 4c

Jul 17, 2025 06:00AM Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR)

Jul 16, 2025 07:01AM Voyager Therapeutics adds fourth alzheimer's program targeting APOE

May 15, 2025 07:02AM Voyager Therapeutics (VYGR) Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 6, 2025 05:35PM Voyager Therapeutics (VYGR) Misses Q1 EPS by 8c

Mar 31, 2025 07:25AM Truist: 'Expect Some Pressure On Dr. Marks' Resignation'

Mar 31, 2025 07:01AM Voyager Therapeutics (VYGR) Presents Robust Preclinical Data from Tau Targeting Gene Therapy

Mar 13, 2025 06:57AM Voyager Therapeutics (VYGR) PT Lowered to $12 at Canaccord Genuity

Mar 13, 2025 06:46AM H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Mar 12, 2025 12:58PM Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Mar 12, 2025 07:40AM Voyager Therapeutics (VYGR) PT Lowered to $11 at Citi

Mar 3, 2025 07:05AM Voyager Therapeutics (VYGR) Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

Feb 11, 2025 07:01AM Voyager Therapeutics (VYGR) Provides Update on SOD1 ALS Gene Therapy Program

Jan 27, 2025 07:22AM H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Dec 2, 2024 05:02AM Citi Starts Voyager Therapeutics (VYGR) at Buy

Nov 13, 2024 10:53AM Oppenheimer Reiterates Outperform Rating on Voyager Therapeutics (VYGR)

Nov 12, 2024 04:16PM Voyager Therapeutics (VYGR) Tops Q3 EPS by 29c

Oct 4, 2024 02:46PM Voyager Therapeutics (VYGR) November 5 and 10 calls active as share price up 15%

Sep 26, 2024 02:12PM Truist Securities Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Sep 25, 2024 06:53AM Baird Reiterates Outperform Rating on Voyager Therapeutics (VYGR)

Sep 16, 2024 07:02AM Voyager Therapeutics (VYGR) Advances Collaboration with Neurocrine

Sep 5, 2024 08:09AM Voyager Therapeutics (VYGR) Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

Aug 20, 2024 06:44AM H.C. Wainwright Reiterates Buy Rating on Voyager Therapeutics (VYGR)

Aug 6, 2024 04:14PM Voyager Therapeutics (VYGR) Tops Q2 EPS by 23c

Jun 13, 2024 07:00AM Voyager Therapeutics (VYGR) Appoints Nathan Jorgensen as CFO